Literature DB >> 12115111

Thrombocytopenia secondary to linezolid administration: what is the risk?

Joanne J Orrick, Thomas Johns, Jennifer Janelle, Reuben Ramphal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12115111     DOI： 10.1086/341310

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  13 in total

1.  Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.

Authors:  Emma Bishop; Sharmila Melvani; Benjamin P Howden; Patrick G P Charles; M Lindsay Grayson
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy.

Authors:  Chao Chen; Dai-Hong Guo; Xiutang Cao; Yun Cai; Yuanjie Xu; Man Zhu; Liang Ma
Journal:  Curr Ther Res Clin Exp       Date:  2012-12

3.  Reply to Hardalo et al., "Myelosuppression with Oxazolidinones: Are There Differences?"

Authors:  Aisling R Caffrey; Erica Yookyung Lee
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

4.  A propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with Gram-negative bacteremia.

Authors:  Hugo-Guillermo Ternavasio-de la Vega; Ana-María Mateos-Díaz; Jose-Antonio Martinez; Manel Almela; Nazaret Cobos-Trigueros; Laura Morata; Cristina De-la-Calle; Marta Sala; Josep Mensa; Miguel Marcos; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

5.  Thrombocytopenia with Tedizolid and Linezolid.

Authors:  Erica Yookyung Lee; Aisling R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

6.  Safety and Tolerability of More than Six Days of Tedizolid Treatment.

Authors:  Mireia Mensa Vendrell; Maria Tasias Pitarch; Miguel Salavert Lletí; Eva Calabuig Muñoz; Laura Morata Ruiz; Genís Castells Lao; Ester López Suñé; Jose Mensa Pueyo; Maria Rosa Oltra Sempere; Maria-Luisa Pedro-Botet Montoya; Valentina Isernia; Esteban Alberto Reynaga Sosa; Leonor Moreno Nuñez; Juan Pasquau Liaño; Sergio Sequera Arquelladas; José Ramón Yuste Ara; Alex Soriano Viladomiu
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 7.  Linezolid: in infants and children with severe Gram-positive infections.

Authors:  Katherine A Lyseng-Williamson; Karen L Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Clinical population pharmacokinetics and toxicodynamics of linezolid.

Authors:  Lauren M Boak; Craig R Rayner; M Lindsay Grayson; David L Paterson; Denis Spelman; Sharmila Khumra; Blair Capitano; Alan Forrest; Jian Li; Roger L Nation; Jurgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

9.  Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.

Authors:  Thomas P Lodise; Edward Fang; Sonia L Minassian; Philippe G Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

10.  Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress.

Authors:  Tian-Lin Wang; Dai-Hong Guo; Yan Bai; Ke Wen; Wen-Yan Han; Rui Wang
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.